Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026)

Sagimet Biosciences' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 40.76% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$39.7 million (up 21.74% YoY), while the FY2025 annual figure was -$45.6 million, down 7.58% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$8.6 million, up from -$11.8 million in the prior quarter.
• The five-year high for Free Cash Flow was -$3000.0 in Q2 2022, with the low at -$19.6 million in Q3 2024.
• The 5-year median for Free Cash Flow is -$7.3 million (2022), against an average of -$8.4 million.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 190566.67% in 2023, then jumped 47.98% in 2025.
• Sagimet Biosciences' Free Cash Flow stood at -$7.5 million in 2022, then advanced by 4.96% to -$7.1 million in 2023, then slumped by 55.64% to -$11.0 million in 2024, then fell by 7.34% to -$11.8 million in 2025, then rose by 27.23% to -$8.6 million in 2026.
• Business Quant data shows SGMT's Free Cash Flow at -$8.6 million in Q1 2026, -$11.8 million in Q4 2025, and -$10.2 million in Q3 2025.